Invitris

Invitris is a biotechnology startup that operates in the healthcare sector, specifically in the field of drug-resistant infections. The company has developed a universal platform technology that enables the generation of synthetic phages, a type of virus that infects and eradicates bacteria, at high yields and purity. This technology is being used to create phage-based drugs with new mechanisms of action to treat infections that have become resistant to traditional drugs.

Invitris' business model revolves around the development and commercialization of these phage-based drugs. Their target market includes healthcare providers and patients suffering from drug-resistant infections, a growing global issue that is predicted to cause 10 million deaths per year, surpassing the mortality rate of cancer.

The company's vision is to create a world where any bacterial infection can be effectively cured by bacteriophages. To achieve this, they are leveraging their unique technology to develop highly effective drugs that can cure infections where other drugs have failed.

Invitris' revenue generation strategy is likely based on the sales of their phage-based drugs to healthcare providers and patients. As a service provider, they are also liable under general law for their own content on their platform, and they have a responsibility to monitor and remove any information that indicates illegal activity.

In summary, Invitris is a biotech startup that is developing innovative solutions to tackle the global issue of drug-resistant infections. Their unique technology and ambitious vision position them as a promising player in the healthcare sector.

Keywords: Biotechnology, Healthcare, Drug-Resistant Infections, Synthetic Phages, Phage-Based Drugs, Universal Platform Technology, Bacteriophages, Novel Therapeutic Mechanisms, Service Provider, Revenue Generation.